calcium channel, voltage-dependent, N type, alpha 1B subunit |
SULOCTIDIL |
Calcium Channel Type L, Dihydropyridine |
100% |
.2595uM |
.1668uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
SULOCTIDIL |
Calcium Channel Type L, Dihydropyridine |
100% |
.2595uM |
.1668uM |
View
|
prostaglandin-endoperoxide synthase 2 |
HEXACHLOROPHENE |
Cyclooxygenase COX-2 |
100% |
.6443uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
HEXACHLOROPHENE |
Cyclooxygenase COX-2 |
100% |
.6443uM |
NoneNone |
View
|
mitogen activated protein kinase 3 |
HEXACHLOROPHENE |
Protein Serine/Threonine Kinase, ERK1 |
100% |
2.4844uM |
NoneNone |
View
|
mitogen-activated protein kinase 3 |
HEXACHLOROPHENE |
Protein Serine/Threonine Kinase, ERK1 |
100% |
2.4844uM |
NoneNone |
View
|
mitogen activated protein kinase 14 |
HEXACHLOROPHENE |
Protein Serine/Threonine Kinase, p38alpha |
100% |
.0876uM |
NoneNone |
View
|
mitogen-activated protein kinase 14 |
HEXACHLOROPHENE |
Protein Serine/Threonine Kinase, p38alpha |
100% |
.0876uM |
NoneNone |
View
|
epidermal growth factor receptor |
HEXACHLOROPHENE |
Protein Tyrosine Kinase, EGF Receptor |
100% |
.7486uM |
NoneNone |
View
|
Protein-tyrosine kinase, Fyn |
HEXACHLOROPHENE |
Protein Tyrosine Kinase, Fyn |
100% |
3.478uM |
NoneNone |
View
|
lymphocyte protein tyrosine kinase (mapped) |
HEXACHLOROPHENE |
Protein Tyrosine Kinase, Lck |
100% |
2.4325uM |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, beta |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel associated protein 1 |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel associated protein 2 |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type III, beta |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type I, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
amiloride-sensitive cation channel 5, intestinal |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type III, beta |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type I, beta |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type II, beta |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, nonvoltage-gated 1 gamma |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, nonvoltage-gated 1 beta |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, nonvoltage-gated 1, gamma |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, nonvoltage-gated 1, delta |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type X, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage gated, type VIII, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type IV, beta |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type IV, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type III, alpha |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type II, beta |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type II, alpha 2 |
PERHEXILINE |
Sodium Channel, Site 2 |
100% |
.5106uM |
.4658uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, voltage-gated, type I, beta |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, voltage-gated, type II, beta |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, nonvoltage-gated 1 gamma |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, nonvoltage-gated 1 beta |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, nonvoltage-gated 1, gamma |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, nonvoltage-gated 1, delta |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
sodium channel, voltage-gated, type X, alpha |
CINNARIZINE |
Sodium Channel, Site 2 |
100% |
.414uM |
.377uM |
View
|
amiloride-sensitive cation channel 5, intestinal |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, voltage-gated, type III, beta |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, voltage-gated, type I, beta |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, voltage-gated, type II, beta |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, nonvoltage-gated 1 gamma |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, nonvoltage-gated 1 beta |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
FLUNARIZINE |
Sodium Channel, Site 2 |
100% |
.263uM |
.24uM |
View
|
glycine receptor, alpha 3 |
STRYCHNINE |
Glycine, Strychnine-Sensitive |
100% |
.008295uM |
.004689uM |
View
|
glycine receptor, alpha 1 subunit |
STRYCHNINE |
Glycine, Strychnine-Sensitive |
100% |
.008295uM |
.004689uM |
View
|
glycine receptor, beta subunit |
STRYCHNINE |
Glycine, Strychnine-Sensitive |
100% |
.008295uM |
.004689uM |
View
|
glycine receptor, alpha 2 subunit |
STRYCHNINE |
Glycine, Strychnine-Sensitive |
100% |
.008295uM |
.004689uM |
View
|
mitogen activated protein kinase 14 |
CLOSANTEL |
Protein Serine/Threonine Kinase, p38alpha |
100% |
.656uM |
NoneNone |
View
|
mitogen-activated protein kinase 14 |
CLOSANTEL |
Protein Serine/Threonine Kinase, p38alpha |
100% |
.656uM |
NoneNone |
View
|
thromboxane A synthase 1 |
CLOSANTEL |
Thromboxane Synthetase |
100% |
.064uM |
NoneNone |
View
|
thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
CLOSANTEL |
Thromboxane Synthetase |
100% |
.064uM |
NoneNone |
View
|
arachidonate 15-lipoxygenase, second type |
DOBUTAMINE |
Lipoxygenase 15-LO |
100% |
.599uM |
NoneNone |
View
|
arachidonate 15-lipoxygenase |
DOBUTAMINE |
Lipoxygenase 15-LO |
100% |
.599uM |
NoneNone |
View
|
arachidonate 15-lipoxygenase |
DOBUTAMINE |
Lipoxygenase 15-LO |
100% |
.599uM |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 2B |
METHYLERGONOVINE |
Serotonin 5-HT2B |
100% |
.001505uM |
.000958uM |
View
|
Protein-tyrosine kinase, Fyn |
CLOSANTEL |
Protein Tyrosine Kinase, Fyn |
100% |
.939uM |
NoneNone |
View
|
adrenergic receptor, alpha 2a |
AMITRAZ |
Imidazoline I2, Central |
100% |
.0477uM |
.0318uM |
View
|
adrenergic receptor, alpha 2c (Non-specific probe) |
AMITRAZ |
Imidazoline I2, Central |
100% |
.0477uM |
.0318uM |
View
|
acetylcholinesterase (YT blood group) |
HUPERZINE A |
Acetylcholinesterase |
100% |
.029uM |
NoneNone |
View
|
collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
HUPERZINE A |
Acetylcholinesterase |
100% |
.029uM |
NoneNone |
View
|
acetylcholinesterase |
HUPERZINE A |
Acetylcholinesterase |
100% |
.029uM |
NoneNone |
View
|
adrenergic receptor, alpha 2b |
ALPHA-ERGOCRYPTINE |
Adrenergic alpha2B |
100% |
.026uM |
.012uM |
View
|
5-hydroxytryptamine receptor 6 |
ALPHA-ERGOCRYPTINE |
Serotonin 5-HT6 |
100% |
.016uM |
.007559uM |
View
|
adrenergic receptor, alpha 1a |
ALPHA-ERGOCRYPTINE |
Adrenergic alpha1A |
100% |
.011uM |
.004279uM |
View
|
dopamine receptor D3 |
ALPHA-ERGOCRYPTINE |
Dopamine D3 |
100% |
.000589uM |
.0002uM |
View
|
tachykinin receptor 2 |
BITHIONOL |
Tachykinin NK2 |
100% |
4.659uM |
1.553uM |
View
|
epidermal growth factor receptor |
CLOSANTEL |
Protein Tyrosine Kinase, EGF Receptor |
100% |
.564uM |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 1A |
ALPHA-ERGOCRYPTINE |
Serotonin 5-HT1A |
100% |
.002631uM |
.001503uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2A |
ALPHA-ERGOCRYPTINE |
Serotonin 5-HT2A |
100% |
.047uM |
.014uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2B |
ALPHA-ERGOCRYPTINE |
Serotonin 5-HT2B |
100% |
.013uM |
.008217uM |
View
|
5-hydroxytryptamine (serotonin) receptor 1B |
ALPHA-ERGOCRYPTINE |
Serotonin 5-HT1B |
100% |
.008199uM |
.005021uM |
View
|
prostaglandin-endoperoxide synthase 1 |
TENIDAP |
Cyclooxygenase COX-1 |
100% |
.055uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
TENIDAP |
Cyclooxygenase COX-1 |
100% |
.055uM |
NoneNone |
View
|
protein kinase C, delta |
PACLITAXEL |
Phorbol Ester |
19% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 1 |
BITHIONOL |
Protein Serine/Threonine Kinase, ERK2 |
100% |
.385uM |
NoneNone |
View
|
mitogen-activated protein kinase 1 |
BITHIONOL |
Protein Serine/Threonine Kinase, ERK2 |
100% |
.385uM |
NoneNone |
View
|
Cytochrom P450-1A2 monooxygenase |
TENIDAP |
CYP450-1A2 Inhibition |
100% |
1uM |
NoneNone |
View
|
adrenergic receptor, alpha 2b |
BITHIONOL |
Adrenergic alpha2B |
100% |
1.226uM |
.56uM |
View
|
adrenergic receptor, alpha 1b |
ALPHA-ERGOCRYPTINE |
Adrenergic alpha1B |
100% |
.014uM |
.007938uM |
View
|
cholinergic receptor, muscarinic 2 |
PIPERILATE ETHOBROMIDE |
Muscarinic M2 |
100% |
.026uM |
.009339uM |
View
|
progesterone receptor |
MEDROXYPROGESTERONE ACETATE |
Progesterone |
100% |
.002247uM |
.000293uM |
View
|
progesterone receptor |
MEDROXYPROGESTERONE ACETATE |
Progesterone |
100% |
.002247uM |
.000293uM |
View
|
cholinergic receptor, muscarinic 1 |
PIPERILATE ETHOBROMIDE |
Muscarinic M1 |
100% |
.035uM |
.008387uM |
View
|
prostaglandin-endoperoxide synthase 1 |
3,3',4',5-TETRACHLOROSALICYLANILIDE |
Cyclooxygenase COX-1 |
100% |
.666uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
3,3',4',5-TETRACHLOROSALICYLANILIDE |
Cyclooxygenase COX-1 |
100% |
.666uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 |
3,3',4',5-TETRACHLOROSALICYLANILIDE |
Cyclooxygenase COX-2 |
100% |
.542uM |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 1A |
BUSPIRONE |
Serotonin 5-HT1A |
100% |
.016uM |
.009307uM |
View
|
adrenergic receptor, alpha 2a |
DIHYDROERGOCRISTINE MESYLATE |
Adrenergic alpha2A |
100% |
.001993uM |
.000747uM |
View
|
5-hydroxytryptamine (serotonin) receptor 1A |
DIHYDROERGOCRISTINE MESYLATE |
Serotonin 5-HT1A |
100% |
.000722uM |
.000412uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2B |
DIHYDROERGOCRISTINE MESYLATE |
Serotonin 5-HT2B |
100% |
.006601uM |
.004201uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2B |
ERGOTAMINE |
Serotonin 5-HT2B |
100% |
.003461uM |
.002203uM |
View
|
5-hydroxytryptamine (serotonin) receptor 1B |
ERGOTAMINE |
Serotonin 5-HT1B |
100% |
.000201uM |
.000091uM |
View
|
opioid receptor, kappa 1 |
SPIRADOLINE |
Opiate kappa |
100% |
.0083uM |
.00332uM |
View
|
adrenergic receptor, beta 3 |
(S)-(-)-PINDOLOL |
Adrenergic beta3 |
100% |
.048uM |
.036uM |
View
|
dopamine receptor D3 |
IVERMECTIN |
Dopamine D3 |
100% |
2.2092uM |
.7503uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2B |
LISURIDE |
Serotonin 5-HT2B |
100% |
.005095uM |
.003242uM |
View
|
adrenergic receptor, alpha 2b |
CLONIDINE |
Adrenergic alpha2B |
100% |
.083uM |
.038uM |
View
|
adrenergic receptor, alpha 1b |
BENZTROPINE |
Adrenergic alpha1B |
100% |
.074uM |
.041uM |
View
|
cholinergic receptor, muscarinic 2 |
BENZTROPINE |
Muscarinic M2 |
100% |
.01uM |
.003668uM |
View
|
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
MAPROTILINE |
Adrenergic, Norepinephrine Transporter |
100% |
.03uM |
.03uM |
View
|
glycine receptor, alpha 3 |
ABAMECTIN |
Glycine, Strychnine-Sensitive |
100% |
.132uM |
.075uM |
View
|
glycine receptor, alpha 1 subunit |
ABAMECTIN |
Glycine, Strychnine-Sensitive |
100% |
.132uM |
.075uM |
View
|
glycine receptor, beta subunit |
ABAMECTIN |
Glycine, Strychnine-Sensitive |
100% |
.132uM |
.075uM |
View
|
glycine receptor, alpha 2 subunit |
ABAMECTIN |
Glycine, Strychnine-Sensitive |
100% |
.132uM |
.075uM |
View
|
dopamine receptor D3 |
BUSPIRONE |
Dopamine D3 |
100% |
.044uM |
.015uM |
View
|
cholinergic receptor, muscarinic 3 |
BENZTROPINE |
Muscarinic M3 |
100% |
.001285uM |
.000272uM |
View
|
histamine receptor H 1 |
BENZTROPINE |
Histamine H1, Central |
100% |
.003183uM |
.00037uM |
View
|
arachidonate 15-lipoxygenase, second type |
METHYLDOPA |
Lipoxygenase 15-LO |
100% |
2.126uM |
NoneNone |
View
|
arachidonate 15-lipoxygenase |
METHYLDOPA |
Lipoxygenase 15-LO |
100% |
2.126uM |
NoneNone |
View
|
arachidonate 15-lipoxygenase |
METHYLDOPA |
Lipoxygenase 15-LO |
100% |
2.126uM |
NoneNone |
View
|
melanocortin 5 receptor |
GRAMICIDIN |
Melanocortin MC5 |
100% |
2.013uM |
1.888uM |
View
|
adrenergic receptor, alpha 1b |
MAPROTILINE |
Adrenergic alpha1B |
100% |
.163uM |
.09uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2A |
MAPROTILINE |
Serotonin 5-HT2A |
100% |
.064uM |
.018uM |
View
|
adrenergic receptor, alpha 1d (Non-specific probe) |
DOBUTAMINE |
Adrenergic alpha1D |
100% |
.114uM |
.056uM |
View
|
adrenergic receptor, alpha 2b |
BENZTROPINE |
Adrenergic alpha2B |
100% |
.065uM |
.03uM |
View
|
cholinergic receptor, muscarinic 1 |
BENZTROPINE |
Muscarinic M1 |
100% |
.000544uM |
.000131uM |
View
|
5-hydroxytryptamine receptor 6 |
METHYLERGONOVINE |
Serotonin 5-HT6 |
100% |
.002538uM |
.001178uM |
View
|
5-hydroxytryptamine (serotonin) receptor 1B |
METHYLERGONOVINE |
Serotonin 5-HT1B |
100% |
.015uM |
.009263uM |
View
|
mu-opioid receptor MOR |
NALTREXONE |
Opiate mu |
100% |
.004083uM |
.001657uM |
View
|
adrenergic receptor, alpha 1d (Non-specific probe) |
THIORIDAZINE |
Adrenergic alpha1D |
100% |
.005891uM |
.002895uM |
View
|
protein kinase C, mu |
PACLITAXEL |
Phorbol Ester |
19% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, beta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel associated protein 1 |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel associated protein 2 |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type III, beta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type I, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
amiloride-sensitive cation channel 5, intestinal |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type III, beta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type I, beta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type II, beta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, nonvoltage-gated 1 gamma |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, nonvoltage-gated 1 beta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, nonvoltage-gated 1, gamma |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, nonvoltage-gated 1, delta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type X, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage gated, type VIII, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type IV, beta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type IV, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type III, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type II, beta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type II, alpha 2 |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type I, beta |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
sodium channel, voltage-gated, type I, alpha |
NELFINAVIR |
Sodium Channel, Site 2 |
100% |
1.881uM |
1.686uM |
View
|
adrenergic receptor, alpha 1a |
PROMAZINE |
Adrenergic alpha1A |
100% |
.009238uM |
.003739uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2A |
PROMAZINE |
Serotonin 5-HT2A |
100% |
.023uM |
.006695uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
NITRENDIPINE |
Calcium Channel Type L, Dihydropyridine |
100% |
.000383uM |
.000246uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
NITRENDIPINE |
Calcium Channel Type L, Dihydropyridine |
100% |
.000383uM |
.000246uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
NITRENDIPINE |
Calcium Channel Type L, Dihydropyridine |
100% |
.000383uM |
.000246uM |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
NITRENDIPINE |
Calcium Channel Type L, Dihydropyridine |
100% |
.000383uM |
.000246uM |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
NITRENDIPINE |
Calcium Channel Type L, Dihydropyridine |
100% |
.000383uM |
.000246uM |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
NITRENDIPINE |
Calcium Channel Type L, Dihydropyridine |
100% |
.000383uM |
.000246uM |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
NITRENDIPINE |
Calcium Channel Type L, Dihydropyridine |
100% |
.000383uM |
.000246uM |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
NITRENDIPINE |
Calcium Channel Type L, Dihydropyridine |
100% |
.000383uM |
.000246uM |
View
|